CRVS - Corvus Pharmaceuticals, Inc.

QQQ $ 469.17 $ 0.54 (0.12 %)

DIA $ 408.92 $ -0.54 (-0.13 %)

SPY $ 554.92 $ -0.07 (-0.02 %)

TLT $ 100.11 $ -0.26 (-0.26 %)

GLD $ 235.94 $ 1.30 (0.52 %)

Previous Close

$ 4.57

Open

$ 4.67

Bid

$ 5.00 x 100

Ask

-- x --

Day's Range

$ 4.67 - $ 5.03

52 Week Range

$ 1.05 - $ 4.87

Volume

510,858

Average Volume

Market Cap

285.86M

Beta (5Y Monthly)

$ 1.07

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2024	06-30-2024	10-Q
2	05-07-2024	03-31-2024	10-Q
3	03-19-2024	12-31-2023	10-K
4	11-07-2023	09-30-2023	10-Q
5	08-08-2023	06-30-2023	10-Q
6	05-08-2023	03-31-2023	10-Q
7	03-28-2023	12-31-2022	10-K
8	11-03-2022	09-30-2022	10-Q
9	08-08-2022	06-30-2022	10-Q
10	05-05-2022	03-31-2022	10-Q
11	03-10-2022	12-31-2021	10-K
12	11-01-2021	09-30-2021	10-Q
13	08-02-2021	06-30-2021	10-Q
14	04-29-2021	03-31-2021	10-Q
15	03-25-2021	12-31-2020	10-K
16	10-29-2020	09-30-2020	10-Q
17	07-30-2020	06-30-2020	10-Q
18	04-30-2020	03-31-2020	10-Q
19	03-09-2020	12-31-2019	10-K
20	10-30-2019	09-30-2019	10-Q
21	08-01-2019	06-30-2019	10-Q
22	05-09-2019	03-31-2019	10-Q
23	03-07-2019	12-31-2018	10-K
24	11-01-2018	09-30-2018	10-Q
25	08-02-2018	06-30-2018	10-Q
26	05-03-2018	03-31-2018	10-Q
27	03-01-2018	12-31-2017	10-K
28	11-02-2017	09-30-2017	10-Q
29	08-03-2017	06-30-2017	10-Q
30	05-04-2017	03-31-2017	10-Q
31	03-10-2017	12-31-2016	10-K
32	11-03-2016	09-30-2016	10-Q
33	08-04-2016	06-30-2016	10-Q
34	05-05-2016	03-31-2016	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

$corvus-pharmaceuticals-initiates-registrational-phase-3-clinical-trial-of-soquelitinib-for-patients-with-relapsedrefractory-peripheral-t-cell-lymphoma$

Corvus Pharmaceuticals Initiates Registrat...
09/10/2024 12:30:37

Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently...

Why Fortinet Shares Are Trading Higher By ...
08/07/2024 10:04:36

Corvus Pharma Q2 EPS $(0.07) Beats $(0.12)...
08/06/2024 20:02:32

Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.12)...

$corvus-pharmaceuticals-announces-fda-fast-track-designation-for-soquelitinib-in-treatment-of-relapsed-or-refractory-ptcl-phase-3-clinical-trial-to-begin-initial-enrollment-in-q3-2024$

Corvus Pharmaceuticals Announces FDA Fast ...
08/01/2024 12:41:45

Corvus Pharmaceuticals Announces Publicati...
07/25/2024 12:35:13

Oppenheimer Maintains Outperform on Corvus...
05/07/2024 12:06:09

Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and raises the price target from $7 t...

Corvus Pharma Expects FY24 Net Cash Used I...
05/06/2024 20:03:58

Corvus Pharma Q1 2024 GAAP EPS $(0.12), In...
05/06/2024 20:02:03

Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate.

Corvus Pharmaceuticals Announces Pricing O...
05/02/2024 12:40:18

Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical compan...

12-health-care-stocks-moving-in-tuesdays-after-market-session

12 Health Care Stocks Moving In Tuesday's ...
04/09/2024 20:31:18

Corvus Pharmaceuticals Announces Initiatio...
04/09/2024 20:02:18

Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's select...

Cantor Fitzgerald Reiterates Overweight on...
04/01/2024 15:16:33

Cantor Fitzgerald analyst Li Watsek reiterates Corvus Pharma (NASDAQ:CRVS) with a Overweight.

Mizuho Maintains Neutral on Corvus Pharma,...
03/27/2024 17:21:58

Mizuho analyst Graig Suvannavejh maintains Corvus Pharma (NASDAQ:CRVS) with a Neutral and maintains $3.5 price target.

Oppenheimer Maintains Outperform on Corvus...
03/20/2024 11:14:14

Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and lowers the price target from $8 t...

Corvus Pharma Q4 EPS $(0.14) Misses $(0.12...
03/19/2024 20:04:29

Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.1...

Earnings Scheduled For March 19, 2024
03/19/2024 10:06:23

Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per...

Earnings Outlook For Corvus Pharma
03/18/2024 14:00:39

Corvus Pharmaceuticals Presents Soquelitin...
02/12/2024 13:31:23

The poster presentation includes the first description of Corvus' next-generation ITK inhibitor preclinical product candida...

12-health-care-stocks-moving-in-fridays-pre-market-session

12 Health Care Stocks Moving In Friday's P...
02/09/2024 13:06:11

12-health-care-stocks-moving-in-thursdays-after-market-session

12 Health Care Stocks Moving In Thursday's...
02/08/2024 21:31:10